PT  - JOURNAL ARTICLE
AU  - Martín-Olalla, José María
TI  - Excess deaths in Spain during the first year of the COVID–19 pandemic outbreak from age/sex–adjusted death rates
AID  - 10.1101/2020.07.22.20159707
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.07.22.20159707
4099  - http://medrxiv.org/content/early/2021/08/15/2020.07.22.20159707.short
4100  - http://medrxiv.org/content/early/2021/08/15/2020.07.22.20159707.full
AB  - Objectives Assess the impact of the illness designated COVID–19 during the first year of pandemic outbreak in Spain through age/sex–specific death rates.Study design Age/sex–specific weeekly deaths in Spain were retrieved from Eurostat. Spanish resident population was obtained from the National Statistics Office.Methods Generalized linear Poisson regressions were used to compute the contrafactual expected rates after one year (52 weeks or 364 days) of the pandemic onset. From this one–year age/sex–specific and age/sex–adjusted mortality excess rates were deduced.Results For the past continued 13 years one–year age/sex–adjusted death rates had not been as high as the rate observed on February 28th, 2021.The excess death rate was estimated as 1.790×10−3 (95 % confidence interval, 1.773×10−3 to 1.808×10−3; P−score = 20.2 % and z−score = 11.4) with an unbiased standard deviation of the residuals equal to 157×10−6. This made 84 849 excess deaths (84 008 to 85 690). Sex disaggregation resulted in 44 887 (44 470 to 45 303) male excess deaths and 39 947 (39 524 to 40 371) female excess deaths.Conclusion With 73 571 COVID–19 deaths and 9772 COVID–19 suspected deaths that occurred in nursing homes during the spring of 2020 it is only 1496 excess deaths (1.8 %, a z−score of 0.2) that remains unattributed.The infection rate during the first year of the pandemic is estimated in 16 % of population after comparing the ENE–COVID seroprevalence, the excess deaths at the end of the spring 2020 and the excess deaths at the end of the first year of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:public information only.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this manuscript come from public records.